Biological characteristics and prognosis analysis of 64 cases of acute erythroid leukemia
-
摘要: 目的:探讨急性红白血病的生物学特点并对预后进行评价。方法:回顾分析2001-07—2011-07的64例急性红白血病患者,针对其形态学、免疫学、细胞遗传学和分子生物学(MICM)特征及生存期进行分析。采用病例对照方法,分为原发组和骨髓增生异常综合征(MDS)转化组,针对2组患者化疗和异基因造血干细胞移植(Allo-HSCT)治疗的疗效和生存预后分析。结果:原发组缓解率为 62%(24/39),MDS转化组缓解率为 47%(8/17),2者间差异无统计学意义(P>0.05)。染色体核型异常组和正常组的缓解率分别为41%(10/24)和69%(22/32),2者间差异有统计学意义(P<0.01)。MDS转化组17例,化疗与移植1年总生存率(OS)分别为25.0%和88.9%,差异有统计学意义(P<0.01)。染色体核型异常组24例,化疗与移植组1年OS分别为25.0%和85.6%,差异有统计学意义(P<0.01)。结论:64例患者中常规化疗疗效差、生存期短、预后差,Allo-HSCT显著延长生存期,改善预后,染色体核型异常患者诊断后宜早期行Allo-HSCT。Abstract: Objective:To evaluate the prognosis and the biological characteristics of acute erythroid leukemia.Method:The data of 64 cases of acute erythroid leukemia which were treated in our hospital between July 2001 and July 2011 were retrospectively analyzed.The feature of morphology,immunology,cytogenetics,molecular biology(MICM) and survival time were analyzed.Case-control method was used,and all cases were divided into two groups,namely primary group and myelodysplastic syndromes (MDS) transform group.The two groups were analyzed by comparing the treatment effect of chemotherapy and allogeneic hematopoietic stem-cell transplantation (Allo-HSCT), and survival prognosis.Result:The remission rate of primary group and MDS transform group was 62% (24/39)and 47 % (8/17),respectively,and there were no statistically significant difference (P>0.05).The remission rate of chromosome abnormalities group and normal group was 41% (10/24) and 69% (22/32),respectively,and there was a statistically significant difference (P<0.01).The one year overall survival rate(OS) of chemotherapy and Allo-HSCT in MDS transform group including 17 cases was 25% and 88.9%,respectively,are there were a statistically significant difference (P<0.01).The one year overall survival rate(OS) of chemotherapy and Allo-HSCT in chromosome abnormalities group including 24 cases was 25% and 85.6%,respectively,and there was a statistically significant difference (P<0.01).Conclusion:In the 64 cases,chemotherapy often had poor treatment effect,short survival time and poor prognosis,meanwhile Allo-HSCT could increase survival time and improve prognosis,chromosome abnormalities patients should perform early Allo-HSCT.
-
-
[1] LU D P,DONG L J,WU T,et al.Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation[J].Blood,2006,107:3065-3073.
[2] 张之南.血液病诊断及疗效标准[M].2版.北京:科学出版社,1998:215-216.
[3] DOMINGO-CLAROS A,LARRIBA I,ROZMAN M,et al.Acute erythroid neoplastic proliferations.A biological study based on 62 patients[J].Haematologica,2002,87:148-153.
[4] HASSERJIAN R P,ZUO Z,GARCIA C,et al.Acute erythroid leukemia:a reassessment using criteria refined in the 2008 WHO classification[J].Blood,2010,115:1985-1992.
[5] BENE M C,CASTOLDI G,KNAPP W,et al.Proposals for the immunological classification of acute leukemias.European group for the immunological characterization of leukemias (EGIL)[J].Leukemia,1995,9:1783-1786.
[6] SANTOS F P,FADERL S,GARCIA-MANERO G,et al.Adult acute erythroleukemia:an analysis of 91 patients treated at a single institution[J].Leukemia,2009,23:2275-2280.
[7] KUCHENBAUER F,KERN W,SCHOCH C,et al.Detailed analysis of FLT3 expression levels in acute myeloid leukemia[J].Haematologica,2005,90:1617-1625.
[8] KILLICK S,MATUTES E,POWLES R L,et al.Acute erythroid leukemia (M6):outcome of bone marrow transplantation[J].Leuk Lymphoma,1999,35:99-107.
[9] FOUILLARD L,LABOPIN M,GORIN N C,et al.Hematopoietic stem cell transplantation for de novo erythroleukemia:a study of the European Group for Blood and Marrow Transplantation (EBMT)[J].Blood,2002,100:3135-3140.
[10] SELBY D M,VALDEIR,SCHNITZER B,et al.Diagnostic criteria for acute erythor leukemia[J].Blood,2003,101:2895-2896.
-
计量
- 文章访问数: 217
- PDF下载数: 166
- 施引文献: 0
下载: